GSK To Scoop Clinical Stage US Biotech Affinivax For $3.3B To Shore Up Vaccine Business

  • GSK plc GSK agreed to acquire U.S. biotech Affinivax for up to $3.3 billion, Reuters reports.
  • The purchase price includes $2.1 billion upfront and $1.2 billion in potential milestones. 
  • Affinivax offers GSK its next-generation vaccines under development, the most advanced for pneumonia, meningitis, bloodstream infections, and sinusitis.
  • Affinivax's newer vaccine technology aims to strengthen the breadth of immunity against a pathogen such that an immune-boosting adjuvant is not necessary.
  • The deal marked GSK's second in two months, offering it access to Affinivax's roster of next-generation vaccines, Reuters notes.
  • GSK's newer shingles vaccine has been a critical growth driver following pandemic recovery.
  • However, GSK needs a new product to bolster the vaccines business ahead of the separation of its consumer business, home to brands like Sensodyne toothpaste and Advil painkillers.
  • The acquisition could serve as a massive breakthrough for GSK, battling Pfizer, Inc PFE and Moderna, Inc MRNA using newer mRNA technology.
  • Price Action: GSK shares traded lower by 0.18% at $43.98 in the premarket on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: M&ANewsMediaBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!